Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proliposomal paclitaxel - LIPAC Oncology

Drug Profile

Proliposomal paclitaxel - LIPAC Oncology

Alternative Names: LEIPC-1007; LEIPC-1008; LEITP-1009; LiPax; PLIP; TBC-1002; TSD 001; TSD 005; UTUC 1005

Latest Information Update: 16 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TesoRx
  • Developer LIPAC Oncology; TesoRx
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer
  • Preclinical Mesothelioma; Ovarian cancer; Peritoneal cancer; Pleural effusion; Urogenital cancer

Most Recent Events

  • 16 Mar 2023 Preclinical development in Urogenital-cancer is ongoing in USA (Intraluminal) (TesoRx pipeline, March 2023)
  • 16 Mar 2023 Phase-II clinical trials in Bladder cancer in USA (Intravesicular) prior to March 2023 (TesoRx pipeline, March 2023)
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Urogenital-cancer in USA (Intraluminal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top